Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

    Interact with the Regeneron Pipeline

    Select Therapeutic Area(s):
    Select Phase(s):
    Select Collaborator(s):

    Displaying item(s)

    Clear Filters

    Regeneron Pipeline: Phase 1 Medicines Regeneron Pipeline: Phase 1 Medicines
    • REGN-COV2
      SARS-CoV-2 Antibodies Treatment for hospitalized patients and non-hospitalized patients with COVID-19
      PD-1 Antibody Cancer
    • REGN3767
      LAG-3 Antibody Solid tumors, advanced hematologic malignancies
    • REGN1979
      CD20 X CD3 Antibody B-cell malignancies
    • REGN4018*
      MUC16 X CD3 Antibody Platinum-resistant ovarian cancer
    • REGN5458*
      BCMA X CD3 Antibody Multiple myeloma
    • REGN5459*
      BCMA X CD3 Antibody Multiple myeloma
    • REGN5678
      PSMA X CD28 Antibody Prostate cancer
    • REGN5093
      MET X MET Antibody MET-altered advanced non-small cell lung cancer (NSCLC)
    • REGN5713-5714-5715
      Bet v 1 Antibodies Birch Allergy
    Regeneron Pipeline: Phase 2 Medicines Regeneron Pipeline: Phase 2 Medicines
      VEGF-Trap High-dose (8mg) for wet age-related macular degeneration (AMD)
      PD-1 Antibody Basal cell carcinoma (BCC), metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), neoadjuvant CSCC
    • REGN1979
      CD20 X CD3 Antibody B-cell non-Hodgkin lymphoma
      IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis
      IL-4R Antibody Grass allergy, peanut allergy
    • REGN1908-1909
      Fel d 1 Antibodies Cat allergy
    • REGN3500*
      IL-33 Antibody Asthma, chronic obstructive pulmonary disease (COPD)
    • REGN5069
      GFRα3 Antibody Osteoarthritis pain of the knee
      Activin A Antibody Fibrodysplasia Ossificans Progressiva (FOP)
      ANGPTL-3 Antibody Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia
      C5 Antibody Paroxysmal nocturnal hemoglobinuria, CD-55 deficient protein-losing enteropathy
    • REGN4461
      LEPR Antibody Generalized lipodystrophy
    Regeneron Pipeline: Phase 3 Medicines Regeneron Pipeline: Phase 3 Medicines
      VEGF-Trap Retinopathy of prematurity (ROP)
      PD-1 Antibody non-small cell lung cancer (NSCLC), cervical cancer, adjuvant cutaneous squamous cell carcinoma (CSCC)
      PCSK9 Antibody Homozygous familial hypercholesterolemia (HoFH) in adults and pediatric patients, heterozygous familial hypercholesterolemia in pediatric patients
      ANGPTL-3 Antibody Homozygous familial hypercholesterolemia (HoFH)
      IL-4R Antibody Atopic dermatitis in pediatric patients 6 mo.–11 y.o., asthma in pediatric patients 6-11 y.o., eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic spontaneous urticaria
      IL-6R Antibody Hospitalized "critical" COVID-19 patients, polymyalgia rheumatica, giant cell arteritis
    • REGN-EB3
      Ebola Virus Antibodies Ebola virus infection
      NGF Antibody Osteoarthritis pain of the knee or hip

    No results found, please adjust your filter selection and try again.

    * In collaboration with Sanofi

    ? In collaboration with Teva and Mitsubishi Tanabe

    This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.